Amicus Therapeutics
Stock Forecast, Prediction & Price Target
Amicus Therapeutics Financial Estimates
Amicus Therapeutics Revenue Estimates
Amicus Therapeutics EBITDA Estimates
Amicus Therapeutics Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $305.51M N/A | $329.23M 7.76% | $399.35M 21.29% | Avg: $641.91M Low: $612.01M High: $701.77M avg. 60.73% | Avg: $841.40M Low: $813.99M High: $881.95M avg. 31.07% | Avg: $1.05B Low: $1.02B High: $1.11B avg. 25.88% | Avg: $1.27B Low: $1.23B High: $1.33B avg. 20.20% |
Net Income
% change YoY
| $-250.46M N/A | $-236.56M 5.54% | $-151.58M 35.92% | Avg: $65.11M Low: $8.85M High: $156.43M avg. 142.95% | Avg: $211.34M Low: $106.25M High: $295.16M avg. 224.55% | Avg: $363.05M Low: $347.68M High: $385.79M avg. 71.78% | Avg: $529.32M Low: $506.91M High: $562.49M avg. 45.79% |
EBITDA
% change YoY
| $-196.10M N/A | $-191.88M 2.15% | $-92.07M 52.01% | Avg: $-421.15M Low: $-460.42M High: $-401.53M avg. -357.38% | Avg: $-552.03M Low: $-578.63M High: $-534.05M avg. -31.07% | Avg: $-694.95M Low: $-728.44M High: $-672.31M avg. -25.88% | Avg: $-835.40M Low: $-875.66M High: $-808.19M avg. -20.20% |
EPS
% change YoY
| -$0.92 N/A | -$0.82 10.86% | -$0.51 37.80% | Avg: $0.21 Low: $0.03 High: $0.53 avg. 141.15% | Avg: $0.72 Low: $0.36 High: $1 avg. 243.13% | Avg: $1.23 Low: $1.18 High: $1.31 avg. 70.78% | Avg: $1.79 Low: $1.72 High: $1.91 avg. 45.79% |
Operating Expenses
% change YoY
| $470.96M N/A | $495.06M 5.11% | $427.65M -13.61% | Avg: $449.17M Low: $428.25M High: $491.06M avg. 5.03% | Avg: $588.77M Low: $569.59M High: $617.14M avg. 31.07% | Avg: $741.19M Low: $717.05M High: $776.92M avg. 25.88% | Avg: $890.99M Low: $861.97M High: $933.93M avg. 20.20% |
FAQ
What is Amicus Therapeutics stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 121.27% in 2025-2028.
We have gathered data from 8 analysts. Their low estimate is 8.85M, average is 65.11M and high is 156.43M.
What is Amicus Therapeutics stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 34.47% in 2025-2028.
We have gathered data from 9 analysts. Their low revenue estimate is $612.01M, average is $641.91M and high is $701.77M.
What is Amicus Therapeutics stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 125.21% in 2025-2028.
We have gathered data from 8 analysts. Their low earnings per share estimate is $0.03, average is $0.21 and high is $0.53.
What is the best performing analyst?
In the last twelve months analysts have been covering Amicus Therapeutics stock. The most successful analyst is Tazeen Ahmad.